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Introduction
The cause of cancer is mainly because of two reasons: those 
with an environmental cause and those with a hereditary cause and 
also a leading killing disease in the world. Common environmental 
factors leading to cancer include: tobacco, diet, obesity, infections, 
radiation, lack of physical activity, and environmental pollutants [1]. 
These environmental factors cause or enhance abnormalities in the 
genetic material of cells may leads to cancer [2]. Cell reproduction is 
an extremely complex process that is normally tightly regulated by 
several classes of genes, including oncogenes and tumour suppressor 
genes. Hereditary or acquired abnormalities in these regulatory genes 
can lead to the development of cancer. Small percentage of different 
types of cancer, like familial adenomatous polyposis, breast cancer 
is entirely hereditary. Many types of cancer are caused by a series of 
mutations. Each mutation alters the behaviour of the cell. Cancer is 
fundamentally a disease of failure of regulation of tissue growth. 
In order for a normal cell to transform into a cancer cell, the genes 
which regulate cell growth and differentiation must be altered [3]. 
The affected genes are divided into two broad categories; oncogenes 
are genes which promote cell growth and reproduction. Tumour 
suppressor genes are genes which inhibit cell division and survival. 
Malignant transformation can occur through the formation of novel 
oncogenes, the inappropriate over-expression of normal oncogenes, 
or by the under-expression or disabling of tumour suppressor genes. 
Typically, changes in many genes are required to transform a normal 
cell into a cancer cell [4]. Genetic changes can occur at different levels 
and by different mechanisms. The gain or loss of an entire chromosome 
can occur through errors in mitosis. More common are mutations, 
which are changes in the nucleotide sequence of genomic DNA. 
Some environments make errors more likely to arise and propagate. 
Such environments can include the presence of disruptive substances 
called carcinogens, repeated physical injury, heat, ionising radiation, 
or hypoxia [5]. Chemo resistance to metastatic malignant melanoma is 
due to over expression of p-gp on cell membrane [6]. P-gp expression is 
suppressed by IL2 would help in cancer chemotherapy where the drugs 
are p-gp substrates and the presence of 5′ translated fragment in p-gp 
improves its translational efficacy [7,8]. 
P-gp over expression is one of the reasons to develop multi drug
resistance and inhibition of P-gp helps in the cancer treatment [9-11]. 
Invasive cancers that are confined within the wall of the colon (TNM 
stages I and II) are often curable with surgery, Colorectal cancer 
is the third most commonly diagnosed cancer in the world, but it is 
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Abstract
Study background: Studies on p-glycoprotein was carried out world vide with cell lines like Caco2, MDR1-
LLC-PK1 and MDR1-MDCK in-vitro, but most of the results were failed to produce similar results in-vivo. In the 
present study curcumin inhibitory action on p-glycoprotein increased permeability of irinotecan, so in the colon 
cancer it would be beneficial if curcumin used as add on therapy.
Methods: Intra-rectal administered of N-Nitroso N-methyl urea (2 mg/Kg) induced colon cancer. Single pass 
whole length of colon in-situ perfusion was carried out in rats with irinotecan to study the influence of p-glycoprotein 
modulators like verapamil and curcumin. The rats were divided in to 5 groups (n=6), Group I served as control 
perfused with 30 μg/ml of irinotecan, propronolol and phenol red. Group II was cancerous group, induced by 
N-methyl N-nitroso urea. Group III was perfused with irinotican in cancerous rats. Group IV, perfused with irinotican
in presence of verapamil and group V was pre-treated with curcumin and then perfused with irinotican and was
estimated by HPLC-UV to effective permeability coefficient.
Results: Our qRT-PCR and Western blot results confirmed that about 15-fold decreases in the expression 
of p-glycoprotein (P-gp) in curcumin treated colon cancer cells. Irinotecan was increased to 0.00066 cm/s and 
about 11-fold increase in verapamil-coperfused group, where curcumin pre-treated group irinotecan was increases 
0.00006 cm/s to 0.00042 cm/s that is about 7-fold increase p-glycoprotein inhibitory activity by verapamil and 
curcumin found to be significantly enhanced the cancerous colon permeability of irinotecan.
Conclusions: Any safe suitable p-glycoprotein inhibitors along with irinotecan will enhance the therapeutic 
benefit in the treatment of the colon cancer.
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more common in developed countries [12]. ATP-binding cassette 
transporters (ABC-transporter) are members of a protein super family. 
ABC transporters are transmembrane proteins that utilize the energy 
of adenosine triphosphate (ATP) hydrolysis to carry out certain 
biological processes including translocation of various substrates across 
membranes and non-transport-related processes such as translation 
of RNA and DNA repair. They transport a wide variety of substrates 
across extra- and intracellular membranes, including metabolic 
products, lipids, sterols, and drugs. ABC transporters are involved in 
tumor resistance, cystic fibrosis, bacterial multidrug resistance, and 
a range of other inherited human diseases [13]. In vitro and animal 
studies have proven that curcumin has antitumor, antioxidant, anti-
arthritic, antiamyloid, anti-ischemic and inflammatory properties. Its 
potential anticancer effects stem from its ability to induce apoptosis in 
cancer cells without cytotoxic effects on healthy cells. Curcumin can 
interfere with the activity of the transcription factor NF-κB, which has 
been linked to a number of inflammatory diseases such as cancer [14-
16]. Curcumin affected expression of metallothionein genes, tubulin 
genes, p53 and other genes involved in colon carcinogenesis [17]. 
Curcumin has multiple therapeutic activities against the diseases of the 
cardiovascular, loss of bone and muscle, depression and neuropathic 
pain [18]. The present study illustrates the P-gp inhibitory activity of 
curcumin using irinotecan as P-gp substrate by a novel method with in 
situ cancerous colonic single pass perfusion method in rats.
Irinotecan is an anticancer drug having pharmacoresistance. 
P-glycoprotein, an efflux transporter, is located on the apical membrane 
of colon epithelial cells, oriented such that P-gp substrates are secreted 
from the epithelial cell into the colon lumen. P-gp mediated efflux 
has the potential to decrease colon drug absorption. Inhibition of 
colon P-glycoprotein may have clinically significant effects on the 
cellular concentration of irinotecan. To test this hypothesis, first time 
these studies were conducted to examine the effects of inhibition 
of P-glycoprotein on the absorption of irinotecan in intrarectal 
administered drug (2 mg/Kg N-Nitroso N-methyl urea) induced 
perfusion cancerous rat model.
Materials and Methods
Materials 
Irinotecan Hydrochloride, verapamil Hydrochloride, propranolol 
and curcumin purchased from Sigma Aldrich, Bangalore, India. 
Phenol Red was purchased from Himedia, Mumbai, India. Methanol, 
orthophosphoricacid and phosphate buffer saline purchased from 
Merck Chemicals, Mumbai, India.
Methods
Gene expression studies through qRT-PCR: TRIzol reagent 
(Invitrogen) was used to isolate total ribonucleic acid (RNA) from 
the control and treated cells. Briefly Caco-2 cells were plated out in 
6 well plates and treated with desired concentration of verapamil, 
irinotecan, curcumin and combination of verapamil and curcumin for 
24-hrs before RNA extraction. The concentration of RNA present in 
the samples was determined by measuring the absorbance at 260nm 
using Corona SH-1000 lab absorbance microplate reader. The isolated 
RNA was converted into cDNA using reverse transcription polymerase 
chain reaction (RT-PCR). The cDNA was amplified using quantitative 
real time polymerase chain reaction (qRT-PCR) which helps in 
detection of amplified DNA in real time. Annealing temperature of 
65°C was used (Forward: GCCTGGCAGCTGGAAGACAAATAC; 
Reverse: ATGGCCAAAATCAAGGGTTAGC) and the cycle was set 
for 60 repeats. The qRT-PCR reaction mixture (7.5 µl SYBR® green 
premix (Bio Rad), 0.4 µl forward primer, 0.4 µl reverse primer, 1 µl 
cDNA template per sample and RNase free water to make the volume 
of reaction mixture up to 15 µl) was prepared in standard Bio Rad PCR 
plates and incubated in iQ5 optical system software for quantitative 
expression analysis. The 2^^ct values were calculated using actin as the 
control and the graph was plotted with these values. The amplified DNA 
was run on an agarose gel for further analysis of the gene expression.
Western blotting: Western blotting was performed for checking the 
regulation of P-gp markers. Briefly cell lysate samples after treatment 
were loaded onto an 8% sodium dodecyl sulphate polyacrylamide gel 
(SDS-PAGE) in the concentration of 120 μg/ml. After electrophoresis 
the proteins were transferred from the gel onto a PVDF membrane 
(GE Healthcare Life Sciences). The membrane was first activated by 
incubating it in methanol for 2-min, then washed with Milli-Q for 
10-min and finally was allowed to soak in transfer buffer. The mini 
transblot (Bio Rad) sandwich assembly was used for transferring the 
gel. The gels were washed in the transfer buffer and then transferred 
using a Bio Rad tank at 100V for 1-hr. 45 min (P-gp).
Post transfer the membranes were washed with 1X TBS, 3 times for 
5-min each and then incubated in 2% skim milk as the blocking solution 
for 1 hour. The membranes were washed again in 1X TBS thrice and then 
incubated in primary antibody that was diluted in the ratio of 1:250 for 
one hour at room temperature (mouse monoclonal MDR-1 from Santa 
Cruz, sc-55510). After this the membranes were washed 3 times with 
1X TBST and 2 times with 1X TBS for 5 minutes each. The membranes 
were then incubated with secondary antibody (anti-mouse HRP, Cell 
Signalling, and CS7076) in the dilution concentration of 1:2500 for one 
hour at room temperature. After probing with secondary antibody, the 
membranes were washed 4 times with 1X TBST and 2 times with 1X 
TBS for 5-min each. The membranes were then dried and activated 
using ECL detection system (GE Healthcare Life Sciences) for 2-min 
and then viewed using a Bio Rad Chemi Doc XRS camera with the help 
of Quantity One software. 
Animal studies: For in-situ perfusion studies, Swiss Albino rats of 
either sex aged seven weeks (weighing 270-350 g) are procured from 
the Central Animal House, after getting permission from Institutional 
Animal Ethical Committee (IAEC/09/UCPSc/KU/2011), Kakatiya 
University, Warangal. The animals were placed in polypropylene cages, 
4 per cage, with free access to standard laboratory diet and water. They 
were kept at 25 ± 1°C and 45–55% relative humidity with a 12-hrs light/
dark cycle. 
Colon cancer induction in rats and intrarectal administration 
of drugs: Colon cancer induction in rats was done as described [19]. 
Briefly, twenty Swiss Albino rats of either sex aged seven weeks should 
be administered an intrarectal dose of 2 mg/Kg N-Nitroso N-methyl 
urea dissolved in 0.5 ml of water three times weekly for five weeks to 
induce colon cancer. 
Identification of Aberrant Crypt Foci in Rodents: Aberrant 
crypt loci (ACF) are one of the earliest putative preneoplastic, and in 
some cases, neoplastic lesions in human colons. These microscopic 
lesions identified on methylene blue-stained mucosa with a low-
power-magnification microscope and which are thought to be closely 
related to the earliest steps in multistage colonic tumorogenesis.
ACF are microscopic flat foci of abnormally widened crypts and are 
considered to be one of the earliest histologically identifiable putative 
preneoplastic lesions in colonic mucosa. These lesions are identified on 
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methylene blue-stained mucosa screened on a dissecting microscope. 
Several pieces of evidence indicate the preneoplastic and, in some 
cases, early neoplastic nature of these lesions. In a carcinogen-induced 
colonic tumorogenesis model, these lesions may show dysplastic 
morphology and precede formation of adenomas and adenocarcinoma. 
Immediately after bowel resection, fresh resected colonic segments 
were opened longitudinally, and mucosa from macroscopically normal 
segments were dissected from the underlying layers, spread over on a 
what man paper, and fixed in 10% buffered formalin solution. After 48 
hrs, mucosal strips were immersed in 0.1% methylene blue solution 
for 5 to 10-min and screened fewer than 40X magnification for ACF. 
Methylene blue-stained ACF were easily identified as flat, slightly 
elevated hyper chromatic lesions with widened crypt mouth. Randomly 
selected ACF were micro dissected with a rim of normal surrounding 
mucosa, paraffin embedded, and serially cut perpendicular to the 
surface. The dissected foci were stained with hematoxylineosin (H&E) 
and evaluated for proliferative activity with an anti-proliferating 
cell nuclear antigen (PCNA) antibody using immunohistochemical 
staining. PCNA immunostaining was performed on 5 µm sections. 
After paraffin removal with xylene, rehydration, and blockage of 
endogenous peroxidise activity, the slides mounted in 0.01 mol/L 
sodium citrate buffer were micro waved in a Sharp microwave. 
Microwave was used for antigen retrieval. The nonspecific binding 
sites were blocked with 10% goat nonimmune serum, and the slides 
were incubated with a primary mouse anti- PCNA antibody PC10 at 
1:50 dilution, followed by use of the avidin-biotinimmunoperoxidaze 
method. AEC (3-amino-9-ethylcarbazole) was used as a chromogen. 
The slides were counterstained with Mayer’s hematoxylin. Appropriate 
positive (human tonsils and sub mucosal lymphoid follicles) and 
negative controls (use of nonimmune mouse serum) were used for 
evaluation of PCNA staining. PCNA nuclear immunoreactivity in 
crypt cells was counted separately for basal, middle, and upper third of 
vertically oriented crypts and expressed as labelling index, which was a 
percentage of positively stained nuclei out of total number of nuclei in 
a given crypt section. PCNA-LI staining was compared separately for 
basal, middle, and upper compartments of the ACF and of the normal 
adjacent mucosa in the same slide.
Study design: Following an overnight fasting, rats were divided 
into 5 groups (n=6). The rats we retreated as following, and then 
subjected for colon in-situ perfusion method [20].
Group I: Perfusion of Irinotecan [21] (30 µg/ml) + Propranolol 
(100 µM) + Phenol red (50 mg/ L) in Normal Rats.
Group II: Colon Cancer Induction in Normal Rats by M.N.U 
(N-methyl N-nitroso urea).
Group III: Perfusion of Irinotecan (30 µg/ml +Propranolol (100 
µM) +Phenol red (50 mg/ L) in Colon Cancer Induced Rats.
Group IV: Perfusion of Irinotecan (30 µg/ml) +Propranolol 
(100 µM) +Phenol red (50 mg/ L) + Verapamil (200 µM) in colonic 
cancerous rats.
Group V: Perfusion of Irinotecan (30 µg/ml) + Propranolol (100 
µM) +Phenol red (50 mg/ L) in Curcumin pretreated Colon Cancer 
Induced Rats.
Rat in-situ single-pass colon perfusion: Rats were anaesthetized 
by an intraperitoneal injection of Thiopental Sodium (50 mg/kg) and 
placed on a heated pad to maintain normal body temperature (37°C). 
A midline incision was made on the abdomen and colon segment of 
approximately 8-10 cm was isolated, using the colon-caecal junction 
as a proximal markers reported [22-25]. Semi-circular incisions were 
made at each end, both ends were annulated with PE tubing and legated 
using silk suture and then lumen was rinsed with saline (37°C).Blank 
perfusion buffer was first infused for 5 min at a flow rate of 1 mL/min 
by asyringe pump, followed by perfusion of the compounds studied 
at a constant flow rate of 0.2 mL/min for 90-min, using precalibrated 
perfusion pump. After cannulation, the segment was covered with 
isotonic saline-wet gauze (37°C). The perfusate was collected every 
10 min. At the end of the perfusion, the length of the segment was 
measured following the last collection. The animal was sacrificed by 
injecting saturated solution of KCl (10%). Samples were stored at 
-80oC until analysis and perfusate concentrations of irinotecan were 
quantified using HPLC.
Stability studies: The stability of Irinotecan and propranolol 
were tested by their incubation in the perfusion solution containing 
Phosphate Buffer Saline (pH-7.4) and phenol red at room temperature 
for 6 hrs as reported [26]. Samples were taken at 1, 2, 4 and 6-hrs. Then 
the samples were analysed by RP-HPLC.Drugs were found to be stable 
in perfusion samples for 6-hrs at room temperature. The samples were 
stored at -80°C for short-term stability experiment. There was no sign 
of degradation of drugs and no sign of interaction of drugs with phenol 
red.
Analytical methods: The schimadzu High Performance liquid 
Chromatography unit was equipped with: Solvent delivery module: 
LC-20AD, detector: SPD-20AUV-Visible Spectrophotometer, data 
processor: Class LC-10, Injection Port: Rheodyne (with 20 micro litre 
capacity loop), Column: Merck C-18 column of 25cm length and 
4.6mm internal diameter packed with porous silica spheres of 5 μ 
diameter. Perfusate samples from perfusion experiments were analysed 
using, Reversed Phase HPLC (for irinotecan and propranolol) and 
colorimetry is used for phenol red estimation.
Phenol red assay: The phenol red in phosphate buffer pH (7.4) has a 
characteristic red colour that was measured calorimetrically at 560 nm. 
Phenol red was used as a non-absorbable marker in in-situ technique 
[27]. Phenol red concentration in the outlet perfusate was used to 
assess the steady-state condition in in-situ perfusion technique. It is 
also used to indicate the intestinal mucosa integrity during perfusion.
Irinotecan hydrochloride assay: Irinotecan was detected at 380 
nm, and the mobile phase used is 35% Acetonitrile: 65% KH2PO4 buffer 
pumped at a flow rate of 1ml/min and pressure is maintained with 100 
kg.f/cm.2The sample volume injected was 20μl.
Propranolol assay: Propronolol was detected at 227 nm, and the 
mobile phase used is Methanol 55%: 45% 0.05 mM KH2PO4 (pH -6.0) 
pumped at a flow rate of 1ml/min and pressure is maintained with 
130 kg.f/cm2. The sample volume injected was 20 μl. Propranolol was 
used as a passive, highly permeable marker & as an indicator of major 
changes in mesenteric blood flow [28].
Data analysis by phenol red water flux correction:
Cout (corr) was calculated from the following equation [21]
C out (corr)   = C out× [Concentration of Phenol red in (CPR in)]           
                             [Concentration of Phenol red out (CPR out)]       
Where,
Cout (corr) -corrected outlet concentration of the drug
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Cout -outlet concentration of the drug
CPR in - concentration of phenol red entering the colon Segment
CPR out - concentration of phenol red exiting the colon Segment
Effective permeability coefficient (P eff): It is the quantitative 
estimate of the rate of passage of a solute across a membrane. It is 
calculated from the steady state concentration of compounds in 
the collected perfusate that is considered to be attainable when the 
concentration level of Phenol red is stable. The steady state effective 
permeability is calculated using the following equation as the buffer 
solution is perfused from an entrance in one end of the colon segment 
to an exit at the other end of the colon segment.
Peff=    -Q log [C out (corr)/ C in]
                                2ΠrL
Where, 
P eff    =Effective permeability coefficient
Q     = Perfusion flow rate
C out = Corrected outlet drug concentration.
C in    =Inlet drug concentration
r   =     Radius of small colon
l   =     Length of perfused colon segment
Statistical analysis
Difference in permeability results and difference between the 
concentration time profiles over the entire range tested were analysed 
by two-way ANOVA (Bonferoni post-test). The differences were 
considered to be significant at P < 0.05. Using graph pad prism version 
5.0 performed statistical analyses. 
Results
Verapamil in combination with curcumin inhibits the 
expression of p-gp in Caco-2 cells
We observed a significant inhibition of p-gp expression (P<0.001) in 
verapamil and curcumin treated Caco-2 cells (Figure 1A). Interestingly 
the expression of p-gp was increased in the irinotecan treated caco-2 
cells. There was a synergistic inhibition of p-gp expression (P<0.001) 
observed in the combination treatments of verapamil and curcumin. 
This inhibition was further confirmed in Western blot (Figure 1B). 
Histological studies on the normal rat colon section reviled that 
aberrant crypt foci formation that confirms the induction of cancer in 
the rats with methyl -N-Nitroso urea treated group (Figures 2B & 2C).
Permeability diffrences of irinotecan in normal and cancerous 
rat colon
Colon permeability of irinotecan was determined in rat colon 
segment using in-situ singlepass perfusion technique and the samples 
were analyzed by RP-HPLC method. Effective permeability values were 
calculated from the steady-state concentrations of compounds in the 
perfusate collected from the outlet. Steady-state was confirmed by the 
ratio of the inlet to outlet concentrations (corrected for water transport) 
versus time. Permeability coefficient diffrences of irinotecan in normal 
colon of a rat in comparision to the cancerous colon is because of 
increased cell count, due to which p-gp count is increased because of 
which it is going to result in the decreased permeability coefficient of 
Irinotecan due to increased efflux through p-gp in cancerous colon in 
comparision to normal colon (Figure 3).
Effect of verapamil on colon permeability of irinotecan
Colon permeability of irinotecan was determined in rat colon 
segment using in-situ singlepass perfusion technique and the samples 
were analyzed by RP-HPLC method. Effective permeability values 
were calculated from the steady-state concentrations of compounds 
in the perfusate collected from the outlet. Steady-state was confirmed 
by the ratio of the inlet to outlet concentrations (corrected for water 
transport) versus time. The effective permeability values of irinotecan 
and propranolol in the absence and presence of verapamil a P-gp 
inhibitor.
Colon permeability coefficient of Irinotecan in the absence and 
presence of verapamil was found to be 0.00006 cm/s and 0.00066 cm/s, 
respectively. Verapamil(200 μM), a P-gp inhibitor, co-perfused with 
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Figure 2: Histopathology of colon cancer induced in rats. Panel (A & 
B).Treated groups of cancerous colon showing aberrant crypt foci formation. 
Panel (C).Normal colon cancer showing aberrant crypt foci formation after the 
treatment (that were shown as normal pathology).This is the representative 
histopathology from a field of 100X magnification. All animals in the respective 
group showed similar histopathology with no variations and experiments were 
repeated three times.      
Figure 1: Verapamil in combination with curcumin inhibits the expression 
of p-gp in Caco-2 cells. (A) qRT-PCR and (B) Western blot showing the 
expression of p-gp in the treated and untreated samples with verapamil, 
irinotecan, curcumin and combination of verapamil and curcumin.
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Irinotecan (30 μM) resulted in significant increase in colon permeability 
by 11-fold from (0.00006 to 0.00066 cm/sec). Colon permeability 
coefficient of Irinotecan in the absence and presence of Curcumin was 
found to be 0.00006 cm/s and 0.00042 cm/s, respectively. Curcumin 
(50 mg/kg) pretreatment for a period of one week through per oral 
route resulted in the significant increase in the colon permeability by 
7- fold. Colon permeability coefficient of propranolol in the absence 
and presence of verapamil was found to be 0.000079 cm/s and 0.000087 
cm/s, respectively, which was found to be statistically insignificant. 
Colon permeability coefficient of propranolol in the absence and 
presence of Curcumin was found to be 0.000079 cm/s and 0.000085 
cm/s, respectively, which was found to be statistically insignificant. 
Propranolol is highly permeable marker was shown to have no 
interaction with P-gp (Figure 4).
Discussion 
Irinotecan belonging to the class II drug according to the BCS 
classification is having very low solubility and high permeability. 
Although the drug is having high permeability, in the cancerous 
conditions, there is going to be huge increase in the cell count because 
of which the P-gp count is also going to get increased, due to which 
the permeability of the drug will be reduced and do not have greater 
therapeutic benefit.
Colon permeability for a variety of drugs obtained from in situ single 
pass colon perfusion experiments have shown excellent correlation 
with human perfusion studies [29,30]. Also, in situ colon permeability 
of irinotecan were well correlated with corresponding human results 
in terms of whether these drugs being actively absorbed or they are 
subject to simple passive diffusion [31]. In addition, permeability 
parameters obtained from in situ colon perfusion model provided a 
better prediction of human absorption than the cell based assays [32].
Although drug-drug interactions of irinotecan with verapamil have 
already been described earlier using Caco-2 cells model and in vivo in 
rats [33]. Here we have applied improved in-situ model that allowed us 
to determine the colon permeability of the parent drug. 
The colon permeability is the propensity of a compound to move 
across the epithelial barrier of the colon. In-vitro and in-situ absorption 
models, such as in situ perfusion of rat colon, Caco-2 cell monolayer 
model, MDCK cell lines and excised colon segments in the using 
chamber, are commonly used to investigate transport mechanism. 
Classify permeability and to predict the in-vivo absorption of drugs 
in humans [34]. Among the various models, cell-based assays using 
Caco-2 and MDCK cell lines are commonly utilized for assessing the 
colon permeability of compounds. However, these cell lines are mostly 
used to predict passive absorption and the results obtained are greatly 
affected by experimental parameters such as pH and co-solvents 
[35]. In contrast, in-situ approaches provide experimental conditions 
closer to what is encountered following oral administration, with 
a lower sensitivity to pH variations due to a preserved microclimate 
above the epithelial cells [36]. FDA recognized the in situ single pass 
colon perfusion technique as a useful model to classify a compound’s 
absorption characteristics in the BCS [37]. These techniques maintain 
an intact blood supply to the colon, and can be used to estimate the 
impact of clearance pathways, such as enzymes and transporters, 
that are present in the gut. In addition, it was reported that oral drug 
absorption in rats and humans is very similar [38]. Thus, it is likely that 
the colon perfusion conducted in rats may give a better prediction of 
the fraction of oral dose absorbed in humans than in in-vitro models.
In the present study, in-situ single pass colon perfusion was 
performed in colon segment of rats to investigate the functional role 
of P-gp in colon permeability of irinotecan. Effective permeability of 
irinotecan (30 μg/ml) was significantly increased by co-perfusion with 
verapamil (200 μM). It has been previously reported that verapamil is a 
P-gp inhibitor and improves the colon permeability of paclitaxol (P-gp 
substrate) by blocking the P-gp mediated efflux [28]. Thus the increase 
in irinotecan colon permeability with verapamil is attributable to the 
P-gp modulating ability of verapamil. These results were indicated that, 
P-gp limits the colon permeability of irinotecan by extruding it back to 
the colon. Phenol red was used as a non-absorbable marker in in-situ 
technique [39]. Phenol red concentration in the outlet perfusate was 
used to assess the steady-state condition in in-situ perfusion technique. 
Curcumin is responsible for the reversal of resistance by the 
suppression of P-gp expression [40]. Curcumin mimics are potent 
MDR reversal activity by inhibiting drug efflux function of P-gp, and 
few of them were moderately potent for efficient cancer chemotherapy 
[41]. Curcumin is also beneficial in a genetic mouse model of 
cholangiopathy and biliary fibrosis [42]. Curcuminoids as modulators 
extended the MDR reversing capacity those were purified from 
curcumin used concomitantly in conventional chemotherapy [39]. 
P-glycoprotein inhibitors results in increased bioavailability of P-gp 
drug substrates there by increasing the therapeutic benefit [43]. There is 
the evidence of in-vivo evidence of ABCG2-mediated efflux inhibition 
by curcumin with non-toxic concentrations where drug absorption 
is mediated by ABCG2 [44]. P-gp is a major cause of the efflux of 
drugs; the various effects of inhibitors of this protein in the form of 
0.003
0.002
0.001
0.000
P
ef
f  
(c
m
/s
ec
)
No
rm
al
Co
lon
 Ca
nc
er 
ind
uc
ed
Comparision of Peff  in the colon of normal and cancerous rats
Figure 3: Comparison of Peff in the colon of normal and intrarectal administred 
(2 mg/Kg N-Nitroso N-methyl urea) induced cancerous rats.
0.008
0.006
0.004
0.002
0.000
P e
ff 
  (c
m
/s
ec
)
Irin
ote
can
Pro
pra
no
lol
Without Verapamil
With Verapamil
Without Curcumin
With Curcumin
Figure 4: Comparison of Peff of various treated groups  *** Indicates P < 0.005.
Citation: Neerati P, Sudhakar YA, Kanwar JR (2013) Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon 
Perfusion Rat Model. J Cancer Sci Ther 5: 313-319. doi:10.4172/1948-5956.1000221
Volume 5(9) 313-319 (2013) - 318 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal
nanomedicine are useful in treatment of various types of cancer [45]. 
There is the evidence of in-vivo evidence of ABCG2-mediated efflux 
inhibition by curcumin with non-toxic concentrations where drug 
absorption is mediated by ABCG2 [46]. Curcumin a non-steroidal 
anti-inflammatory drug (NSAID) acts as chemosensitizer in order 
to reverse in vitro MDR by inhibiting P-gp, and proved as potential 
sensitizer in anti-cancer chemotherapy [47]. It is also used to indicate 
the colon mucosa integrity during perfusion. Propranolol was used as 
a passive, highly permeable marker & as an indicator of major changes 
in mesenteric blood flow [28]. The permeability values of propranolol 
(highly permeable maker) in the absence and presence verapamil 
was found to be statistically insignificantly. Therefore indicating that 
changes in irinotecan permeability in the presence of verapamil is not 
due to compromise in membrane integrity.
Conclusion
In colon cancer, oral treatment with irinotecan is convenient to 
patients and facilitates the use of more chronic treatment regimens. 
In the present study, we have shown that P-gp can decrease the colon 
permeability of irinotecan by effluxing it back to colon. P-gp inhibitory 
activity of verapamil resulted in significant improvement in colon 
permeability of irinotecan. There is also significant improvement in 
the permeability of irinotecan with curcumin. The observed effect may 
be beneficial in a way to reduce the pharmcoresistance of irinotecan 
by using any safe P-gp inhibitors to improve its oral bioavailability. 
Clinically, concomitant oral administration of verapamil or any safe 
P-gp inhibitors with irinotecan in colon cancer treatment would 
allow dose reduction and more importantly, the risk of metabolic 
saturation with irinotecan could be substantially reduced because of 
reduced dose and lowered accumulation of drug in body. The results 
of this study could be utilized to evaluate different dosing strategies for 
irinotecan with any safe P-gp inhibitors in patients with colon cancer. 
The combination of anti-cancer drugs and P-gp inhibitory natural 
molecule formulations led to increase the drug uptake and a significant 
improvement of the therapeutic effect of anti-cancer drugs in resistant 
tumour cells as well as cancer resistance stem cells. Thus this first time 
reported animal perfusion method may be useful and can be applied 
to assess the effect of different pharmaceutical and/or natural bioactive 
compounds for their potential to improve the intestinal permeability 
and decrease the toxicity for the purpose of evaluating novel oral nano 
or non-nano formulations based on p-gp inhibition.
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